Humacyte (HUMA) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $25.00 price target on the stock.
Humacyte Submits Marketing Authorization Application for Symvess® in Israel for Vascular Trauma Repair [Yahoo! Finance]
Humacyte Submits Marketing Authorization Application for Symvess® in Israel for Vascular Trauma Repair
Humacyte, Inc. (HUMA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]
Humacyte, Inc. (HUMA) Presents at TD Cowen 46th Annual Health Care Conference Transcript [Seeking Alpha]